alexa Is It Possible To Reverse The Motor Alterations With Dopamine Supply Content In An Amorphous Matrix In A Hemiparkinsonian Rat Model?
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

9th Annual European Pharma Congress
June 26-28, 2017 Madrid, Spain

P Vergara-Aragon, G Valverde-Aguilar, Ruth Bustamante-García1, Teresa Neri-Gomez and Marcela Palomero-Rivero
Universidad Nacional Autónoma de México, Mexico
CICATA-Legaría Instituto Politécnico Nacional, Mexico
Centro Médico Nacional Siglo XXI- IMSS, Mexico
Posters & Accepted Abstracts: Pharmaceut Reg Affairs
DOI: 10.4172/2167-7689-C1-025
The aim of this study was to evaluate the effect that applies an amorphous matrix with dopamine obtained by sol-gel method produces in the caudate nucleus of induced hemiparkinsonian rats. The estimation of this matrix with dopamine effects was evaluated by behavioral, histological and neurochemical tests. We used 64 male Wistar rats about 250-300 g aleatory divided in 4 groups of 8 each one with free access to water and food. The groups that conformed each experimental block were: Control (C), Lesioned (Lx); Lesion + implant (Lx-IMP) and Implant (Imp). The behavioral evaluation was made on day 1, 21, 90, 180 and 360 of the experimental phase. It was made an evaluation of the exploratory behavior and induced twist. We exanimated the fine motor in the reach test, number of induced twist with APO and we determinate the DA levels by HPLC in the SN and NC. The results showed differences (p<0.05) between Lx group compared with control in the test made. Also, we found statistically significant differences between Lx and Lx+Imp groups with reports of improvement in the implant group. These results suggest that the dopamine was released through the nanoporos that has the matrix with dopamine walls resulting in a frank rise in the number of squares walk in the open field test for the Lx+Imp group, less number of induced rotations, better performance in the reaching task and superior dopamine levels compare with Lx group. With these results we can conclude that a matrix with dopamine implanted in the NC of hemiparkinsonian rats causes a beneficial effect that we attributed to the released dopamine in the rats with hemiparkinsonism + implant caudate nucleus.
Acknowledgement: The authors acknowledge the financial supports of SIP 20170002, DGAPA-PAPIIT IT200813 and DGAPA PAPIIT IT202417

P Vergara-Aragón has done her MD and PhD in Psychological Research and has worked in the Faculty of Medicine UNAM in Mexico for more than 30 years. She is collaborating with the Physics Institute of the National Polytechnique Institute. Her research is focused on the field of Parkinson Disease (PD): Study of the nigrostriatal pathway degeneration, and involved mechanism caused by rotenone and 6-OHDA; stabilization of dopamine and its use as treatment for PD; the study of the effects produced in vivo of a TiO2 amorphous matrix as a reservoir for dopamine in a PD model in rats; description of the cognitive implications of PD in patients; toxicity and biological implications of rotenone exposure in animal models.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version